# Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months

> **NCT06904274** · PHASE3 · RECRUITING · sponsor: **Bayer** · enrollment: 207 (estimated)

## Conditions studied

- Endometrial Hyperplasia

## Interventions

- **COMBINATION_PRODUCT:** BAY865028
- **DRUG:** Medroxyprogesterone acetate

## Key facts

- **NCT ID:** NCT06904274
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-24
- **Primary completion:** 2027-08-02
- **Final completion:** 2027-08-02
- **Target enrollment:** 207 (ESTIMATED)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06904274

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06904274, "Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06904274. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*